NVNO — enVVeno Medical Corp

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1661053 ·
Last close
$11.25
Market Cap
$7.51M
52W High
$13.44
52W Low
$9.01
ADV30
12,024
Next earnings
enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -4,062,000 -3,849,000 26,097,000 2,597,000 2,350,000
Dec 2025 0 -4,013,000 -3,736,000 29,562,000 3,065,000 2,432,000
Sep 2025 0 -4,883,000 -4,539,000 32,352,000 1,544,000 2,905,000
Jun 2025 0 -7,049,000 -6,694,000 36,577,000 2,044,000 3,520,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-15,568,000
Investing CF
$15,856,000
Financing CF
$1,023,000
CapEx
$-13,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-39.55
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-171,327,000
Inventory
Receivables
ST Investments
$25,147,000
EBIT TTM
$-20,899,000
Pretax Income TTM
$-19,472,000
Interest Exp TTM
Analysts

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -20,899,000 -19,472,000 29,562,000 2,432,000 -15,568,000
Dec 2024 0 -23,826,000 -21,819,000 44,954,000 2,795,000 -16,838,000
Dec 2023 0 -25,238,000 -23,516,000 48,635,000 2,435,000 -18,858,000
Dec 2022 0 -24,932,000 -24,669,000 41,661,000 2,932,000 -15,619,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.19

Peers — same industry

TickerNameMarket CapLastDaily %
USAQ QHSLab, Inc. $7.82M $0.52
TNON Tenon Medical, Inc. $8.01M $0.69
NDRA ENDRA Life Sciences Inc. $6.60M $5.20
INBS INTELLIGENT BIO SOLUTIONS INC. $6.34M $2.65
MHUAF Meihua International Medical Technologies Co., Ltd. $6.33M $7.40

News headlines (Yahoo Finance, 1h cache)

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment
2026-05-12 13:02 · Yahoo
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System
2026-05-07 12:05 · Yahoo
One enVVeno Medical Insider Raised Their Stake In The Previous Year
2026-05-06 18:58 · Yahoo
enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve
2026-04-29 12:05 · Yahoo
enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System
2026-03-27 12:30 · Yahoo
NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives
2026-03-03 19:40 · Yahoo
enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-02-04 13:30 · Yahoo
enVVeno Medical Announces Reverse Stock Split
2026-01-15 13:00 · Yahoo
enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment
2025-11-26 13:48 · Yahoo
Insider Buyers Lose Additional US$294k As enVVeno Medical Dips To US$6.5m
2025-11-22 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.